FiercePharma |
ACC: Novartis' canakinumab cuts CV risks in patients with kidney ...
FiercePharma ORLANDO, Fla.—When Novartis released results from a 10000-patient trial examining canakinumab—already approved as rare disease med Ilaris—last year, analysts initially questioned its future as a cardio drug. Now, the drugmaker is touting two new ... Canakinumab Does Not Appear to Prevent Diabetes Onset - MPR |
from diabetes - Google News
Social Plugin